[Skip to Content]
[Skip to Content Landing]
Views 217
Citations 0
Correction
February 28, 2019

Errors in eTable 6 in the Supplement

JAMA Ophthalmol. 2019;137(4):467. doi:10.1001/jamaophthalmol.2019.0032

In the Original Investigation titled “Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial,”1 an incorrect analysis of the mean deviations for visual field loss over time led to errors in eTable 6 in Supplement 3. These errors did not affect the conclusions of the article. A Letter of Explanation2 has been published that details the source of these errors. This article has been corrected online.

References
1.
Gross  JG, Glassman  AR, Liu  D,  et al; Diabetic Retinopathy Clinical Research Network.  Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial.  JAMA Ophthalmol. 2018;136(10):1138-1148. doi:10.1001/jamaophthalmol.2018.3255PubMedGoogle ScholarCrossref
2.
Glassman  AR.  Incorrect data in supplement  [published online February 28, 2019].  JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2019.0001Google Scholar
×